During the last session, Agile Therapeutics Inc. (NASDAQ:AGRX)’s traded shares were 0.3 million, with the beta value of the company hitting 1.58. At the end of the trading day, the stock’s price was $1.63, reflecting an intraday loss of -1.21% or -$0.02. The 52-week high for the AGRX share is $69.60, that puts it down -4169.94 from that peak though still a striking 3.07% gain since the share price plummeted to a 52-week low of $1.58. The company’s market capitalization is $6.28M, and the average intraday trading volume over the past 10 days was 0.46 million shares, and the average trade volume was 336.68K shares over the past three months.
Agile Therapeutics Inc. (AGRX) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 1.70. AGRX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.13.
Agile Therapeutics Inc. (NASDAQ:AGRX) trade information
Agile Therapeutics Inc. (AGRX) registered a -1.21% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.21% in intraday trading to $1.63 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -8.94%, and it has moved by -78.21% in 30 days. Based on these gigs, the overall price performance for the year is -97.47%. The short interest in Agile Therapeutics Inc. (NASDAQ:AGRX) is 1.62 million shares and it means that shorts have 1.08 day(s) to cover.
The consensus price target of analysts on Wall Street is $6.40, which implies an increase of 74.53% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6.40 and $6.40 respectively. As a result, AGRX is trading at a discount of -292.64% off the target high and -292.64% off the low.
Agile Therapeutics Inc. (AGRX) estimates and forecasts
Statistics show that Agile Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Agile Therapeutics Inc. (AGRX) shares have gone down -94.50% during the last six months, with a year-to-date growth rate more than the industry average at 51.95% against 6.80. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 35.00% this quarter and then jump 40.00% in the quarter after that. In the rating firms’ projections, revenue will increase 463.40% compared to the previous financial year.
Revenue for the current quarter is expected to be $1.63 million as predicted by 3 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to $2.3 million by the end of Mar 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $749k and $160k respectively. In this case, analysts expect current quarter sales to grow by 117.60% and then jump by 1,337.50% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 5.40%. While earnings are projected to return -26.00% in 2022.
Agile Therapeutics Inc. is due to release its next quarterly earnings between May 02 and May 06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Agile Therapeutics Inc. (NASDAQ:AGRX)’s Major holders
Agile Therapeutics Inc. insiders own 1.04% of total outstanding shares while institutional holders control 34.68%, with the float percentage being 35.04%. Perceptive Advisors Llc is the largest shareholder of the company, while 60 institutions own stock in it. As of Sep 29, 2021, the company held over 15.92 million shares (or 13.11% of all shares), a total value of $15.3 million in shares.
The next largest institutional holding, with 4.1 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 3.38% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $3.95 million.
Also, the Mutual Funds coming in first place with the largest holdings of Agile Therapeutics Inc. (AGRX) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Sep 29, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 2.74 million shares. This amounts to just over 2.26 percent of the company’s overall shares, with a $2.64 million market value. The same data shows that the other fund manager holds slightly less at 1.18 million, or about 0.97% of the stock, which is worth about $1.14 million.